Salivary Melatonin Profile: Which Tests to Order Alongside

What a Salivary Melatonin Profile Actually Measures

The test captures your pineal gland's melatonin secretion curve across a single evening-to-morning window. Saliva samples are collected every 30 to 60 minutes under dim-light conditions (typically <30 lux), starting 5 to 6 hours before your usual bedtime and continuing through the night. The critical data point is the DLMO, defined as the clock time when salivary melatonin concentration first exceeds a fixed threshold, most commonly 3 pg/mL or 4 pg/mL depending on the assay [1].

DLMO is the gold-standard biomarker for circadian phase timing, per the 2015 American Academy of Sleep Medicine (AASM) clinical practice guideline on intrinsic circadian rhythm sleep-wake disorders [2]. A DLMO that occurs more than 2 hours later than expected relative to desired bedtime supports a diagnosis of delayed sleep-wake phase disorder (DSWPD). A DLMO that fires abnormally early may point toward advanced sleep-wake phase disorder (ASWPD).

But phase timing alone is not the full picture. A patient with a perfectly timed DLMO can still sleep poorly if cortisol is elevated at night, ferritin is low enough to trigger restless legs, or hypothyroidism is dragging sleep architecture. That is why the melatonin profile gains its real diagnostic power only when paired with the right companion labs.

Why the Melatonin Profile Alone Is Not Enough

Melatonin tells you where the clock is set. It does not tell you whether the clock's downstream targets are responding, whether other hormones are overriding the signal, or whether a nutrient deficiency is fragmenting sleep independently of circadian phase [3].

A 2020 review in the Journal of Clinical Sleep Medicine identified that 38% of patients referred for circadian evaluation had a comorbid condition (hypothyroidism, iron deficiency, or obstructive sleep apnea) that independently disrupted sleep and required separate treatment [4]. Ordering the melatonin profile without screening for these conditions risks treating the wrong problem.

Think of the melatonin profile as one axis on a graph. Without the second axis, you cannot locate the patient's position.

The Core Paired Test: Salivary Cortisol Rhythm

The single most informative companion to the melatonin profile is a four-point salivary cortisol diurnal curve, with samples at waking, 30 minutes post-waking (to capture the cortisol awakening response, or CAR), afternoon, and bedtime [5].

Melatonin and cortisol normally run in opposition. Cortisol peaks within 30 to 45 minutes of waking (typical morning values: 0.25 to 0.60 µg/dL in saliva) and drops to its nadir (<0.09 µg/dL) around midnight, precisely when melatonin is climbing. A flattened cortisol slope, where evening cortisol remains above 0.15 µg/dL, has been associated with insomnia severity, metabolic syndrome, and depression in multiple cohort studies [6].

When the melatonin onset is appropriately timed but the cortisol nadir is absent or blunted, the clinical picture shifts from a circadian disorder to a stress-axis or HPA-axis dysregulation problem. This distinction changes the treatment plan entirely: light therapy and melatonin supplementation address phase errors, while elevated nocturnal cortisol may call for cognitive-behavioral therapy for insomnia (CBT-I), stress-reduction protocols, or investigation of Cushing syndrome if values are persistently high.

The Endocrine Society's 2008 clinical practice guideline on Cushing syndrome diagnosis recommends late-night salivary cortisol as a first-line screening test, with a cutoff of 0.112 µg/dL (by LC-MS/MS) to prompt further workup [7]. Ordering both profiles on the same collection night is efficient and cost-effective, since the patient is already providing timed saliva samples under controlled conditions.

Thyroid Panel: TSH and Free T4

Hypothyroidism disrupts sleep through multiple mechanisms. Reduced thyroid hormone lowers basal metabolic rate, impairs thermoregulation (which gates sleep onset), and is associated with obstructive sleep apnea via upper-airway myxedema [8]. A 2022 cross-sectional analysis in Thyroid (N=5,994) found that subjects with TSH above 4.5 mIU/L had 1.47 times the odds of reporting poor sleep quality compared to euthyroid controls [9].

TSH and free T4 should be drawn as a fasting morning blood sample. The test is inexpensive, widely available, and can reveal a treatable cause of sleep disruption that no amount of melatonin supplementation will fix. For patients already on levothyroxine, checking a TSH confirms adequacy of dosing.

The AACE/ATA 2012 clinical practice guideline for hypothyroidism recommends a TSH target of 0.45 to 4.12 mIU/L for most adults, with tighter targets (0.45 to 2.5 mIU/L) considered in specific populations such as those planning pregnancy [10].

Iron Studies: Ferritin and Transferrin Saturation

Iron deficiency is the most common medical cause of restless legs syndrome (RLS), a condition that causes sleep-onset insomnia and repeated nocturnal awakenings independent of circadian phase [11]. The International Restless Legs Syndrome Study Group recommends checking serum ferritin in every patient with RLS symptoms and initiating oral iron supplementation when ferritin falls below 75 µg/L, even if the patient is not anemic [12].

Order ferritin alongside transferrin saturation. A ferritin below 75 µg/L with transferrin saturation below 20% supports iron-deficient erythropoiesis as the driver. A low ferritin with normal or high transferrin saturation may indicate an inflammatory state (ferritin is an acute-phase reactant), which is a different clinical pathway.

In the sleep-clinic population, iron deficiency is shockingly common. A 2019 study in Sleep Medicine (N=382) found that 43% of patients referred for insomnia evaluation had ferritin levels below 50 µg/L [13]. Without measuring iron, these patients may receive a circadian diagnosis and circadian treatment while the actual substrate deficiency goes unaddressed.

Vitamin D: 25-Hydroxyvitamin D

The relationship between vitamin D and sleep has moved beyond correlation. A 2022 meta-analysis in Nutrients (20 RCTs, N=2,367) found that vitamin D supplementation improved sleep quality scores (Pittsburgh Sleep Quality Index) by a standardized mean difference of -0.39 (95% CI: -0.61 to -0.17, P<0.001) compared to placebo, with stronger effects in participants whose baseline 25(OH)D was below 20 ng/mL [14].

Vitamin D receptors are expressed in brain regions that regulate sleep, including the hypothalamus and brainstem [15]. A level below 20 ng/mL qualifies as deficient per the Endocrine Society's 2011 clinical practice guideline, which recommends repletion with 50 to 000 IU of ergocalciferol or cholecalciferol weekly for 8 weeks followed by maintenance dosing of 1,500 to 2 to 000 IU daily [16].

Order 25-hydroxyvitamin D as a single morning draw alongside TSH and ferritin to minimize phlebotomy visits.

HbA1c and Fasting Glucose

Hyperglycemia and sleep disturbance form a bidirectional feedback loop. Poor sleep reduces insulin sensitivity; insulin resistance disrupts sleep architecture. A 2015 analysis from the ACCORD trial (N=10,251) demonstrated that participants with HbA1c above 8.0% had significantly higher rates of sleep-disordered breathing and nocturnal awakenings compared to those with HbA1c below 7.0% [17].

For the patient whose melatonin profile is normal but who reports frequent awakenings between 2:00 AM and 4:00 AM, reactive nocturnal hypoglycemia is a diagnostic consideration. An HbA1c below 5.7% and a fasting glucose below 100 mg/dL (per the ADA's 2024 Standards of Care in Diabetes) rule this out efficiently [18]. If HbA1c falls in the prediabetic range (5.7% to 6.4%), treating the metabolic issue may improve sleep independently of any circadian intervention.

Sex Hormones: When to Add Testosterone or Estradiol

Routine sex hormone testing is not indicated for every patient undergoing circadian evaluation. But specific clinical scenarios warrant it.

In men over 40 with fatigue, poor sleep quality, and low libido, a morning total testosterone (drawn before 10:00 AM, fasting) screens for hypogonadism. The Endocrine Society's 2018 guideline defines the lower limit of normal as approximately 264 ng/dL (measured by LC-MS/MS) on two separate morning samples [19]. Testosterone deficiency reduces slow-wave sleep and increases sleep fragmentation, as demonstrated in a 2014 placebo-controlled crossover study published in the Journal of Clinical Endocrinology and Metabolism (N=67), where testosterone replacement increased total sleep time by an average of 23 minutes and reduced the arousal index by 2.1 events per hour [20].

In perimenopausal and postmenopausal women with vasomotor symptoms (hot flashes, night sweats), estradiol and FSH levels help confirm menopausal status and guide hormone replacement decisions. The 2022 Menopause Society position statement notes that vasomotor symptoms are the most common cause of sleep disruption in women aged 45 to 55 and that estrogen therapy reduces nocturnal awakenings by 30% to 50% in symptomatic women [21].

Polysomnography and Actigraphy: Functional Companions

Not every paired test is a blood draw. Two functional assessments round out the melatonin profile's diagnostic reach.

Polysomnography (PSG), the attended overnight sleep study, is indicated when obstructive sleep apnea (OSA) is suspected based on snoring, witnessed apneas, obesity (BMI ≥30), or an Epworth Sleepiness Scale score above 10. OSA affects an estimated 26% of adults aged 30 to 70 in the United States, per data from the HypnoLaus cohort study published in The Lancet Respiratory Medicine (N=2,121) [22]. A patient can have both a circadian phase disorder and OSA simultaneously, and treating only one will produce an incomplete response.

Wrist actigraphy, worn for 7 to 14 consecutive days, provides an objective measure of sleep-wake patterns in the patient's real-world environment. The AASM recommends actigraphy as an adjunct to sleep logs for diagnosing circadian rhythm sleep-wake disorders [2]. The data from actigraphy directly complement the single-night snapshot that the melatonin profile provides, showing whether the phase abnormality persists consistently or varies night to night.

How to Interpret Results as a Panel

A single lab value means little in isolation. Reading the melatonin profile alongside its companion tests follows a systematic logic.

Step 1: Confirm circadian phase. If DLMO is delayed (>2 hours after desired bedtime), the primary diagnosis is DSWPD. If DLMO is advanced (>2 hours before desired bedtime), consider ASWPD.

Step 2: Check cortisol opposition. If evening salivary cortisol is elevated (>0.15 µg/dL) while melatonin onset is normal, HPA-axis activation is the more likely driver of insomnia than circadian misalignment.

Step 3: Screen for substrate deficiencies. Ferritin below 75 µg/L warrants iron repletion. 25(OH)D below 20 ng/mL warrants vitamin D repletion. TSH above 4.5 mIU/L warrants thyroid workup.

Step 4: Rule out metabolic interference. HbA1c in the prediabetic or diabetic range shifts the treatment focus toward glycemic control alongside any circadian therapy.

Step 5: Layer functional data. PSG results revealing an apnea-hypopnea index (AHI) ≥5 events/hour confirm OSA. Actigraphy showing irregular sleep-wake timing over 14 days may suggest irregular sleep-wake rhythm disorder rather than a fixed phase delay or advance.

This layered approach prevents the common error of treating circadian phase in a patient whose real problem is low ferritin or untreated sleep apnea.

Normal Salivary Melatonin Ranges and What Shifts Them

In healthy adults, daytime salivary melatonin sits below 3 pg/mL. The DLMO threshold is typically defined at 3 pg/mL (some assays use 4 pg/mL). Peak nocturnal concentrations range from 40 to 80 pg/mL between 2:00 AM and 4:00 AM, though there is wide inter-individual variation [1].

Age is the strongest predictor of melatonin amplitude. Nocturnal melatonin peaks decline by roughly 10% to 15% per decade after age 30, per a longitudinal analysis published in the Journal of Pineal Research (N=120, follow-up 8 years) [23]. By age 70, some individuals produce peak values below 20 pg/mL.

Several medications suppress melatonin secretion. Beta-blockers (particularly atenolol and propranolol) reduce nocturnal melatonin by 60% to 80% through beta-1 receptor blockade in the pineal gland [24]. NSAIDs (ibuprofen, aspirin) and benzodiazepines also blunt melatonin output. A medication reconciliation before ordering the test is required to avoid false-low results.

Light exposure above 200 lux during the collection window will suppress melatonin and invalidate the test. The sample-collection protocol must enforce dim-light conditions from the start of the sampling window through the final sample.

Raising or Lowering Melatonin: Clinical Approaches

To raise a low or blunted melatonin profile, three evidence-based interventions apply. First, enforce strict dim-light hygiene after sunset (room light below 50 lux, blue-light-filtering lenses). Second, ensure adequate tryptophan intake, since tryptophan is the biosynthetic precursor to serotonin and then melatonin. Third, exogenous melatonin (0.5 to 5 mg, taken 2 to 4 hours before desired DLMO) can phase-advance the circadian clock, as demonstrated by the 2015 AASM practice parameters, which recommend melatonin for DSWPD with a "weak" strength of recommendation based on moderate evidence [2].

To lower an abnormally elevated melatonin profile (rare, but seen in some cases of delayed circadian phase or pineal pathology), timed bright-light exposure in the morning (10,000 lux for 20 to 30 minutes within 1 hour of waking) is the primary intervention. Morning bright light suppresses melatonin production and phase-advances the circadian clock [25]. The combination of morning light and evening melatonin provides the strongest phase-shifting effect, producing shifts of 2 to 3 hours over 1 to 2 weeks in clinical trials.